Strong first quarter performance, with net sales1 of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)
− Biosimilar business growing 21% in constant currencies
− All regions contributing to growth
− Acquisition of CIMERLI (ranibizumab-eqrn) completed in March 2024